Search

Your search keyword '"Chheda, Milan G."' showing total 219 results

Search Constraints

Start Over You searched for: Author "Chheda, Milan G." Remove constraint Author: "Chheda, Milan G."
219 results on '"Chheda, Milan G."'

Search Results

1. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages

2. Tumour evolution and microenvironment interactions in 2D and 3D space

4. Epigenetic regulation during cancer transitions across 11 tumour types

5. Multi-scale signaling and tumor evolution in high-grade gliomas

7. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade

9. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

10. Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

11. Pan-cancer proteogenomics connects oncogenic drivers to functional states

12. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer

14. Zika virus has oncolytic activity against glioblastoma stem cells

15. Proteogenomic and metabolomic characterization of human glioblastoma

16. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

17. Proteogenomic Characterization of Endometrial Carcinoma

18. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

19. Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey

20. ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State

22. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages

24. Pan-cancer proteogenomics connects oncogenic drivers to functional states

25. A pilot phase 1B study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wildtype glioblastoma

26. Data from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

27. Interview with Dr. Mellinghoff from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

28. Supplementary Tables 1-8 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

29. Supplementary Figure and Table Legends, Methods from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

30. Supplementary Figures 1-10 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

31. Supplementary Figure from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

32. Supplementary Data from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

33. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022

36. A path to translation: How 3D patient tumor avatars enable next generation precision oncology

37. NCOG-43. A RETROSPECTIVE ANALYSIS OF THE IMPACT OF THE COVID-19 INFECTION ON NEURO-ONCOLOGY CARE AND PATIENT OUTCOMES: A TWO-SITE STUDY

39. CTIM-10. A PHASE II STUDY OF RETIFANLIMAB (PD-1 INHIBITOR) IN COMBINATION WITH BEVACIZUMAB AND HYPOFRACTIONATED RADIOTHERAPY FOR RECURRENT GLIOBLASTOMA: NCT03532295

42. Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.

45. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models

46. A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma

47. Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma

49. Prospective Biomarker Study in Newly Diagnosed Glioblastoma: Cyto-C Clinical Trial

50. A path to translation: How 3D patient tumor avatars enable next generation precision oncology.

Catalog

Books, media, physical & digital resources